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Restless legs syndrome (RLS), recently renamed Willis–Ekbom 
disease (WED), is a common movement disorder. It is 
characterised by the need to move mainly the legs due to 
uncomfortable, sometimes painful sensations in the legs, 
which have a diurnal variation and a release with movement. 
Management is complex. First, centres should establish the 
severity of RLS using a simple 10-item RLS severity rating 
scale (IRLS). They should also exclude secondary causes, 
in particular ensuring normal iron levels. Mild cases can 
be managed by lifestyle changes, but patients with a IRLS 
score above 15 usually require pharmacological treatment. 
Dopaminergic therapies remain the mainstay of medical 
therapies, with recent evidence suggesting opioids may be 
particularly effective. This article focuses on the different 
treatment strategies in RLS, their associated complications 
and ways to manage them.
KEYWORDS: Restless legs syndrome, RLS, therapy, medical 
treatment, side effects
Introduction
Restless legs syndrome (RLS), also known as Willis–Ekbom 
disease (WED), is a common neurological disorder characterised 
by an uncontrollable urge to move certain parts of the body, 
particularly the lower limbs. This is usually accompanied or 
caused by unpleasant sensations in the legs.1 Symptoms of 
RLS appear or worsen during periods of inactivity or rest and 
improve with activity. The estimated prevalence of RLS ranges 
between 5% and 15%, but fi gures vary widely depending 
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upon the population surveyed and the severity of symptoms 
required for inclusion.2,3 RLS can be categorised as primary 
(idiopathic) or secondary. Secondary RLS occurs as a result of 
certain conditions, such as iron defi ciency, pregnancy, end-stage 
renal disease, diabetes, rheumatoid arthritis and, occasionally, 
peripheral neuropathies. 
Diagnosis
The diagnosis of RLS is based primarily on the patient’s 
clinical history and on a neurological examination to exclude 
peripheral neuropathy. The International RLS Study Group 
(IRLSSG) essential diagnostic criteria for RLS were revised in 
2012 and can be used in clinical practice. They include:4 
1  an urge to move the legs usually accompanied or caused by 
uncomfortable sensations in the legs
2  worsening of symptoms during times of rest or inactivity
3  partial or total relief of symptoms by movement
4  the symptoms only occur or are worse in the evening or night
5  the occurrence of the above features are not solely 
accounted for as symptoms primary to another medical 
or behavioural condition (such as myalgia, venous stasis, 
leg oedema, arthritis, leg cramps, positional discomfort or 
habitual foot tapping).
More recently, a single standard question for rapid screening 
for RLS has been validated.5 The question, developed by the 
IRLSSG on the basis of standard diagnostic criteria, is: ‘When 
you try to relax in the evening or sleep at night, do you ever have 
unpleasant, restless feelings in your legs that can be relieved 
by walking or movement?’. As this single question had 100% 
sensitivity and 96.8% specifi city for the diagnosis of RLS, it can 
be used to screen large patient groups effectively. Nevertheless, 
the fi nal diagnosis should always be confi rmed by matching the 
patient’s history and symptoms with the IRLSSG diagnostic 
criteria, accompanied by the exclusion of secondary conditions.
Treatment
The IRLSSG rating scale (IRLS) for determining the severity 
of RLS consists of 10 questions, each being scored into one of 
fi ve severity categories (from 0 to 4), with the maximum total 
score being 40.6 The severity of RLS symptoms is scored as 
mild (1–10), moderate (11–20), severe (21–30) and very severe 
(31–40). The patient’s score can be used to decide whether 
pharmacological treatment would be benefi cial.
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Non-pharmacological treatment
The majority of RLS cases are mild and can be managed by lifestyle 
changes or non-pharmacological treatment. Lifestyle factors 
known to precipitate RLS symptoms are high caffeine intake7 
(avoid any intake of caffeine before bedtime), excessive alcohol 
consumption8 (avoid any intake of alcohol before bedtime), severe 
stress, shift work and intense physical activity near bedtime. 
Furthermore, sleep hygiene is important and may help patients 
with RLS. It is important, therefore, for patients with RLS to 
consider the following as part of their bedtime routine: 
>  a quiet, comfortable and cool sleeping environment
>  appropriate nightwear (such as silk pyjama or dressing gown)
>  regular sleep pattern (go to bed and wake up at regular 
hours, avoid daytime naps)
>  associate bed with sleep (for instance, avoid watching 
TV from bed).
As RLS usually affects the fi rst part of the sleep cycle at night, 
patients may be advised to alter their sleep pattern by going to 
bed late and waking up late. 
During an attack, patients may benefi t from: 
>  a hot or cold massage, rubbing or massaging the affected 
limbs9
>  bathing in hot or cold water
>  physical activities such as walking, stretching and exercise
>  relaxation exercises (eg biofeedback or yoga)
>  distracting the mind by mental exercises (for example, 
reading an interesting book during the onset of symptoms).
Many other unproven therapies have been described on the 
basis of individual experience, such as the use of capsaicin 
cream or magnesium and halcyon bracelets, but these cannot be 
recommended at this time.
Treating secondary causes
It is important to distinguish between primary and secondary 
RLS. Primary RLS tends to run a chronic course and symptoms 
worsen with time, especially in patients with early onset. By 
contrast, in secondary RLS symptoms may remit once the 
secondary cause (eg iron defi ciency or end-stage renal disease) 
is treated. Iron defi ciency is an important factor even in primary 
RLS; therefore, iron parameters (specifi cally serum ferritin levels) 
should be measured. Those with low or borderline levels require 
oral iron treatment for 1 to 2 months with a repeat measurement 
of serum ferritin levels to avoid iron overload.10 Box 1 summarises 
blood tests necessary to exclude secondary causes of RLS.
Patients with severe RLS and insomnia may require sleep 
studies such as polysomnography11 or immobilisation tests,12,13 
but in practice these are rarely performed in the UK. 
Avoiding medication that exacerbate restless legs 
syndrome
Several drugs are known to worsen RLS symptoms and, if 
possible, these should be avoided. Medications that are known 
to induce or exacerbate RLS symptoms include: antihistamines, 
dopamine antagonists, anti-nausea medications, anxiolytics, 
antidepressants (such as mirtazapine, escitalopram, fl uoxetine 
and mianserin), neuroleptics (such as olanzapine), beta-blockers, 
anticonvulsants, L-thyroxine and lithium.14 In clinical practice, 
it is useful to enquire about medication intake and taper down 
the doses of any antihistamines or dopamine antagonists that are 
being used.
Pharmacological treatment
An estimated 10–15% of RLS patients have symptoms severe 
enough to require medical management of RLS.15 Treatment is 
only required when the symptoms are clinically signifi cant. All 
possible treatment options only address the symptoms and are 
not preventive. Furthermore, as RLS is a chronic disorder, it is 
likely that once the patient starts medication, they will continue 
to use it for the rest of their lives. Therefore, RLS should be 
treated in order to alleviate sensory and motor symptoms, to 
improve sleep and quality of life and to prevent cardiovascular 
complications. The dosage should be kept as low as possible.
Currently, dopaminergic agents are used as fi rst-line treatment 
for moderate to severe RLS. Randomised placebo controlled 
studies have established the effi cacy of dopamine agonists (DA) in 
RLS for both improvement of symptoms and reduction in periodic 
leg movements during sleep and awakening.16 The European 
Federation of Neurological Societies has recommended non-ergot 
DAs, such as ropinirole and pramipexole as tablets or rotigotine as 
patches. In the UK, DAs are the only licensed treatment for RLS. 
The different DAs and their recommended doses are summarised 
in Table 1. The doses are considerably smaller than those used for 
patients with Parkinson’s disease. DAs should be administered as 
a single evening dose and are effective for the short- and long-term 
treatment of idiopathic RLS. If the patient shows intolerance to 
one agent, then another DA should be tried. Oral therapies such 
as pramipexole and ropinirole are both effective, but their use 
depends on tolerability and effi cacy. Rotigotine patches have the 
advantage of being effi cacious during both the day and night, and 
many clinicians prescribe the patch once oral therapies have failed. 
DAs alleviate symptoms in up to 70% of patients. 
Levodopa is used occasionally as the fi rst-line treatment for 
intermittent RLS symptoms (less than three times a week) in 
Germany, Austria and Switzerland. It is mainly used as a rescue 
medication and so is taken when symptoms occur or when they 
are anticipated. Levodopa therapy is associated with a high rate 
of side effects, such as augmentation (an overall increase in RLS 
symptom severity) (60–80%),17 and is not recommended as 
fi rst-line treatment in the UK. Levodopa can also be used as a 
clinical ‘challenge test’ for the diagnosis of RLS.18
Box 1. Recommended blood tests to rule out 
secondary restless legs syndrome.
Iron studies (specifically serum ferritin level is essential)
Full blood count (to exclude anaemia) 
Serum vitamin B12 and folic acid 
Serum glucose and HbA1C 
Urea and electrolytes
Serum creatinine 
Albumin levels (optional)
Thyroid function tests (optional)
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Second-line off-label treatment options for daily RLS symptoms 
are α2δ ligands (such as gabapentin or pregabalin) and opioids 
(such as oxycodone, propoxyphene, tramadol, tilidine or 
codeine). These are particularly useful for patients with painful 
RLS symptoms, coexisting neuropathy or pain elsewhere.19 A 
recent study found that prolonged-release oxycodone-naloxone 
caused an 8-point reduction in the mean IRLS sum score 
compared to placebo. This represents one of the most effective 
treatment responses ever seen in RLS, and so the use of this 
combined medication in severe RLS is likely to be adopted.20
Table 1 summarises the different medications used for the 
treatment of RLS, their recommended minimum start dose, 
maximum dose and main important side effects.
Follow up
RLS patients should be followed up regularly to monitor treatment 
effi cacy, as the disease tends to worsen over time. The European 
Restless Legs Study Group (EURLSSG) recommends that even in 
the absence of complications, patients need to see their physician 
every 6–12 months. A symptom diary completed over 7–14 days 
prior to the consultation could provide the physician with details 
about the severity of symptoms and the effect of treatment. 
If a patient complains of worsening of RLS symptoms while 
being on treatment, the physician should check whether 
the patient is compliant, if they are taking any additional 
medication that may exacerbate symptoms or whether they 
have become more sedentary as this can cause symptoms to 
appear earlier during the day. It is important to check iron 
parameters during follow-up consultations as iron defi ciency is 
implicated in the onset as well as the severity of RLS.10 
Treatment complications
Early morning rebound
Early morning rebound is the reappearance of RLS symptoms 
in the early morning as the effects of medication are wearing 
off. Symptoms tend to be worse than expected if no medication 
was taken but they disappear several hours later. Early morning 
rebound occurs more frequently with short half-life medication 
such as levodopa.21 It is important to exclude concurrent 
conditions, such as depression or sleep apnoea, before 
modifying the current treatment. To manage this complication, 
the dose of the currently prescribed drug can be increased, 
the time of administration can be changed or another 
dopaminergic agent with a longer half-life can be prescribed.22
Tolerance and loss of efﬁ cacy
Tolerance consists of a decrease in the response to a drug over 
time, requiring an increase in dose to achieve the original 
amelioration of symptoms. This is to be differentiated from 
the natural worsening of RLS symptoms, which would also 
require higher drug doses. Unlike rebound or augmentation, 
symptoms are not worse than before treatment initiation. It is 
not completely known whether tolerance inevitably precedes 
and leads to augmentation.
Augmentation
Augmentation is a treatment-related side effect that is 
characterised by an overall increase in RLS symptom severity. It 
is the worst long-term complication of dopaminergic treatment 
Table 1. Pharmacological treatment of restless legs syndrome with recommended dose, time to full 
therapeutic effect, half-life and possible side effects. The side effects are described on the basis of published 
profiles and some relevant case reports. Use of second line drugs can be undertaken after informed discussion and 
choice. Adapted with permission from Garcia-Borreguero et al (2013)13 and Garcia-Borreguero et al (2011).19
Medication Minimal starting 
dose/maximal 
recommended dose
Time to full 
effect of the 
therapeutic dose
Half-life Side effects
Levodopa 50 mg/200 mg At first dose 1.5–2 hours High rates of augmentation and loss of efficacy with rebound 
phenomena.
Ropinirole 0.25 mg/4 mg 4–10 days 6 hours Augmentation, impulse control disorder, nausea, low blood pressure, 
dizziness, headache, nasal congestion, sleepiness in susceptible patients.
Pramipexole 0.125 mg/0.54 mg At first dose 8–12 hours Augmentation, impulse control disorder, nausea, low blood 
pressure, dizziness, headache, nasal congestion, sleepiness in 
susceptible patients.
Rotigotine 1 mg/3 mg 1 week 5–7 hours Skin irritation, low risk of augmentation, nausea, low blood 
pressure, dizziness, headache, nasal congestion, sleepiness in 
susceptible patients. Risk of ICD may be lower.
Pregabalin 25 mg/300 mg 3–6 days 10 hours Sleepiness, dizziness, headache, fluid retention.
Clonazepam 0.50 mg/2.0 mg First dose: effect 
mainly on sleep
30–40 hours High risk of sleepiness, dizziness, morning drug hangover.
Gabapentin 300 mg/2,700 mg 3–6 days 5–7 hours Sleepiness, dizziness, fluid retention.
Tramadol 25 mg/100 mg N/A 5–8 hours Dizziness, sleepiness, constipation, dry mouth
Oxycodone 2.5 mg/25 mg N/A 2–4 hours Dizziness, fatigue, constipation, nausea
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of RLS and leads to worse symptoms than were present before 
treatment had been started. The Max Planck Institute (MPI) 
diagnostic criteria for augmentation are listed in Table 2.
Augmentation occurs more frequently in patients who take 
daily doses higher than the following: 200 mg levodopa, 
0.5 mg pramipexole, 2 mg ropinirole or 3 mg rotigotine. The 
rate of augmentation is greatest with levodopa and among 
the DAs, it is greatest with pramipexole and lowest with 
rotigotine with an incidence of approximately 2–3% per year.24 
Although the vast majority of augmentation cases are due to 
dopaminergic agents, a few cases have been reported with the 
use of tramadol.14,24 No other medication has been found to 
cause augmentation. Predictors of augmentation have been 
identifi ed as low plasma ferritin levels, previous episodes 
of augmentation, longer treatment duration and possibly a 
preceding tolerance to medication.24,25
Several approaches can be taken to prevent augmentation. The 
most effective preventative measure is to prescribe the lowest 
effective dose of dopaminergic medication. Ideally, a low dose 
of a long-acting dopaminergic agent (such as rotigotine) should 
be used; conversely, agents with high rates of augmentation 
(such as levodopa) should be avoided. Another measure is to 
divide the dopaminergic dose, administering the fi rst dose 
earlier in the afternoon before symptom onset and the second 
dose after symptoms started. Divided dose of RLS medication 
has not, however, been approved yet. As low iron body stores 
may be responsible for the augmentation, iron parameters 
should be measured and an oral iron intake must be considered 
if serum ferritin is below 50 µg/l.
When the measures described above are unsuccessful 
and symptoms are so severe that they interfere with the 
patient’s daily activities, a different DA may be prescribed. 
Augmentation is, however, likely to reoccur even when another 
dopaminergic agent is used. If changing dopaminergic agents 
does not improve symptoms, the dopaminergic dose should be 
further reduced while simultaneously initiating treatment with 
a non-dopaminergic agent (such as an α2δ ligand or an opiate), 
until the dopaminergic agent is discontinued altogether.26 
Impulse control disorders
Impulse control disorders (ICD) are a well-known side effect 
of dopaminergic agents in patients with Parkinson’s disease.27 
They have also recently been described in RLS, despite the lower 
doses of dopaminergic medication used by these patients. ICDs 
during RLS treatment are estimated to affect between 3% and 
17% of patients and include obsessive-compulsive behaviour, 
hypersexuality, binge eating, pathologic gambling, punding 
and compulsive shopping.28–30 The incidence of ICDs is dose-
dependent and ceases when dopaminergic treatment is stopped. 
If ICDs occur during treatment with a dopaminergic agent, 
the medication should be either discontinued or progressively 
decreased until the side effect resolves, or until another non-
dopaminergic drug can be substituted or added. 
Weight gain
Sleep loss has been shown to be related to weight gain and obesity.31 
Between 20% and 30% of patients with RLS eat during the night. It 
is important to differentiate weight gain, fl uid retention (oedema) 
and binge eating. Weight gain is also a common side effect of α2δ 
ligands and appears to be dose-dependent. Water retention can also 
occur with dopaminergic agents. 
Mood changes
Depression and anxiety are common comorbid conditions 
associated with RLS.32 Patients with RLS, especially those 
who are taking α2δ ligands, are at greater risk of developing 
depression than healthy individuals. Furthermore, 
augmentation is a common trigger of anxiety. If depression 
Table 2. Max Planck Institute (MPI) diagnostic criteria for augmentation. Adapted with permission from 
Garcia-Borreguero et al (2007).23
Augmentation requires criteria A + B or A + C or A + B + C to be met 
A) Basic criteria 
>  Increase in symptom severity experienced on 5 out of 7 days during the previous week.
>  Increase in symptom severity is not accounted by any other factors (such as change in medication, lifestyle or natural progression of RLS).
>  Positive response to prior treatment. 
In addition, either B or C or both have to be met.
B)  Persisting paradoxical response to treatment: RLS symptom severity increases some time after a dose increase and improves some 
time after a dose decrease.
C)  Earlier onset of symptoms
> by at least 4 hours
>  between 2 and 4 hours plus one of the following points i–iv compared to symptom status before treatment:
i  shorter latency to symptoms when at rest
ii  extension of symptoms to other body parts 
iii  greater intensity of symptoms (or increase in periodic limb movements could be measured by polysomnography or 
immobilisation test)
iv  shorter duration of relief from treatment.
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occurs, the physician should avoid prescribing an antidepressant 
that is known to worsen RLS symptoms, such as a selective 
norepinephrine reuptake inhibitor (SNRI) or a selective 
serotonin reuptake inhibitor (SSRI). Suitable antidepressants 
include duloxetine, buproprion, lamictal, trazadone and 
desipramine. Cognitive behaviour therapy can also be of benefi t.
Conclusions
RLS is a common condition and can have a great impact on quality 
of life, mainly because of disturbed night time sleep and daytime 
sleepiness. Treatment depends on the severity and frequency of 
symptoms, which can be determined by using the IRLSSG rating 
scale. Mild RLS may be managed with reassurance and lifestyle 
changes. Moderate to severe cases require pharmacological 
treatment. Secondary causes and exacerbating factors should be 
identifi ed and treated. Patients with poorly managed RLS can suffer 
from severe morbidity and a poor quality of life associated with 
marked anxiety and, sometimes, depression. ■
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